Tocilizumab for Relapsing Polychondritis

• Status: Withdrawn
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McMaster Children's Hospital

Criteria

Inclusion Criteria:

• A single patient with unremitting inflammatory relapsing polychondritis

Exclusion Criteria:

• As this is a study in a single patient, there are no exclusions